Matthew Biegler
Stock Analyst at Oppenheimer
(1.09)
# 3,656
Out of 4,931 analysts
78
Total ratings
30.43%
Success rate
-13.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Reiterates: Outperform | $32 → $30 | $10.07 | +197.91% | 2 | Jul 31, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $2.10 | +233.33% | 1 | Jul 31, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $10 → $9 | $1.27 | +608.66% | 2 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.05 | +757.14% | 2 | May 14, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $25 → $22 | $4.72 | +366.10% | 6 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $9.63 | +24.61% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $2.07 | +286.47% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $6.24 | +621.15% | 5 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $110.28 | +4.28% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $22.41 | +136.50% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $10.77 | +206.41% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.45 | +1,279.31% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.49 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $10.54 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.82 | +105.28% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.07 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $0.98 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $6.03 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.01 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.25 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $9.97 | +3,510.83% | 1 | Nov 30, 2022 |
Nurix Therapeutics
Jul 31, 2025
Reiterates: Outperform
Price Target: $32 → $30
Current: $10.07
Upside: +197.91%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $2.10
Upside: +233.33%
Acrivon Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.27
Upside: +608.66%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.05
Upside: +757.14%
Olema Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $4.72
Upside: +366.10%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $9.63
Upside: +24.61%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $2.07
Upside: +286.47%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $6.24
Upside: +621.15%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $110.28
Upside: +4.28%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $22.41
Upside: +136.50%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $10.77
Upside: +206.41%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.45
Upside: +1,279.31%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.49
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $10.54
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $6.82
Upside: +105.28%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.07
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $0.98
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $6.03
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.01
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.25
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $9.97
Upside: +3,510.83%